Progress of mechanisms of osimertinib resistance and coping strategies in non-small cell lung cancer
10.3760/cma.j.cn115355-20230112-00027
- VernacularTitle:非小细胞肺癌中奥希替尼耐药机制及应对策略的研究进展
- Author:
Zifang ZHU
1
;
Longhua SUN
;
Xiaolei LI
;
Xinping XU
Author Information
1. 南昌大学第一附属医院呼吸与危重症医学科 江西省呼吸疾病研究所，南昌 330000
- Keywords:
Carcinoma,non-small-cell lung;
Drug resistance, neoplasm;
Epidermal growth factor receptor tyrosine kinase inhibitor;
Osimertinib
- From:
Cancer Research and Clinic
2023;35(9):717-720
- CountryChina
- Language:Chinese
-
Abstract:
Osimertinib, the third generation of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has demonstrated notable clinical benefit in the targeted therapy for patients with non-small cell lung cancer (NSCLC). However, the development of drug resistance is an inevitable challenge. In order to tackle this issue, ongoing efforts are being made to develop new generations of targeted drugs and treatment strategies, some of which are already undergoing clinical trials. This article aims to review the current research on the mechanisms of osimertinib resistance and outline the advancements made in post-drug resistance treatment strategies.
